• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

    5/15/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email

    WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025.

    "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management."

    "We continue to make meaningful progress toward our 2025 priorities, including preparing for international expansion into three new markets later this year for our FOCUSfactor brand and Ready-To-Drink beverages, and expanding our Flat Tummy product line in response to rising interest in GLP-1 support. We also successfully entered into term sheets to refinance our debt that we expect to close as expeditiously as possible, which is expected to accelerate free cash flow in the business in the near term and extend our debt maturity date into 2029. This will provide us the added flexibility to pursue our long-term strategic goals and accelerate our 2025 growth initiatives. With continued momentum and the expected refinancing, Synergy has a clear path forward. We remain confident in our ability to drive sustainable growth and shareholder value. We are truly excited about our ability to accelerate our growth initiatives in the coming quarters."

    First Quarter 2025 Financial Summary vs. Same Year-Ago Period

    • Revenue of $8.2 million vs. $9.4 million.
    • Gross margin of 75.4% vs. 72.0%.
    • Income from operations of $1.9 million vs. $1.8 million.
    • Net income of $876.3 thousand vs. $580.5 thousand.
    • Earnings per share of $0.10 vs. $0.08.
    • EBITDA, a non-GAAP financial measure, was $1.98 million vs. $1.85 million.

    Recent Business Highlights

    • Synergy entered and continued debt refinancing negotiations during and after the first quarter, aiming to extend the maturity to 2029.
    • Synergy has established a wholly owned subsidiary in Mexico and is actively working to onboard several key suppliers and retailers in the region.
    • Synergy signed a new long-term supplier agreement for FOCUSfactor products, effective April 2025, which is expected to deliver significant cost savings.
    • During the first quarter, the Company reduced outstanding liabilities by $1.7 million.

    First Quarter 2025 Financial Results

    Revenue in the first quarter of 2025 was $8.2 million, down 13% compared to $9.4 million in the first quarter of 2024. The decrease was driven by a new product sell-in to one customer in 2024, that did not repeat in 2025.

    Gross margin in the first quarter of 2025 was 75.4% compared to 72.0% in the first quarter of 2024. The increase was largely driven by a favorable shift in product mix.

    Operating expenses in the first quarter of 2025 were $4.2 million, down 15% compared to $5.0 million in the first quarter of 2024. The improvement was driven by management of operating costs and the decrease in net revenue.

    Income from operations for the first quarter of 2025 was $1.9 million, up 8% compared to $1.8 million in the first quarter of 2024. The increase in operating income was due to a decrease in operating expenses.

    Net income in the first quarter of 2025 was $876.3 thousand, up 51% compared to net income of $580.5 thousand in the first quarter of 2024.

    EBITDA (a non-GAAP financial measure) in the first quarter of 2025 was $1.98 million, up 7% compared to $1.85 million in the first quarter of 2024. The increase was primarily due to lower SG&A expenses.

    Balance Sheet and Cash Flow

    As of March 31, 2025, Synergy had approximately $177.9 thousand in cash and cash equivalents, compared to $687.9 thousand in cash and cash equivalents as of December 31, 2024. As of March 31, 2025, Synergy had $31.3 million in total liabilities, compared to $33.0 million in total liabilities as of December 31, 2024, an improvement of $1.7 million.

    As of March 31, 2025, Synergy had $2.3 million in inventory, compared to $1.7 million in inventory as of December 31, 2024.

    Cash used in operating activities for the three months ended March 31, 2025 was $822.8 thousand compared to cash used in operating activities of $858 thousand for the three months ended March 31, 2024.

    EBITDA

    Along with this information, to assist financial statement users in an assessment of our historical performance, the Company discloses non-GAAP financial measures in press releases and on investor conference calls and related events, as the Company believes that the non-GAAP information enhances investors' overall understanding of our financial performance, and should be read in addition to, rather than instead of, the financial statements prepared in accordance with GAAP.

    The following table reconciles net income to EBITDA (in millions of US dollars):

      
      
     3 Months ended March 31
     20252024
       
    Net income for the period$ 0.88$ 0.58
    Adjusted for:  
    Interest expense, net1.081.11
    Amortization of intangible assets0.030.03
    Taxes expense (benefit)(0.01)0.13
    EBITDA$1.98$1.85
       

    Conference Call

    In conjunction with this announcement, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT on May 15, 2025 with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by phone, please register here and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time on the Company's website.

    About Synergy CHC Corp.

    Synergy CHC Corp. is a provider of consumer health care and lifestyle products. Synergy's current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement that has been shown to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products to help women achieve their weight management goals.

    Forward Looking Statements

    Certain statements contained in this press release constitute "forward-looking statements," including statements regarding expansion and growth initiatives, refinancing of our indebtedness and our free cash flow. These forward-looking statements represent Synergy's expectations or beliefs concerning future events, and it is possible that the results described in this press release will not be achieved. These forward-looking statements are subject to risks, uncertainties and other factors, which are set forth in Synergy's registration statement on Form S-1, as amended, many of which are outside of Synergy's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements.

    Any forward-looking statement speaks only as of the date on which it is made, and, except as required by law, Synergy does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Synergy to predict all such factors. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements in Synergy's filings with the SEC. The risk factors and other factors noted in Synergy's filings could cause its actual results to differ materially from those contained in any forward-looking statement.

    Investor Relations



    Gateway Group

    Cody Slach

    949.574.3860

    [email protected]

          
    Synergy CHC Corp.

    Condensed Consolidated Balance Sheets
         
          
     March 31,

    2025
      December 31,

    2024
     
     (unaudited)    
    Assets     
    Current Assets     
    Cash and cash equivalents$177,882  $687,920 
    Restricted cash 100,000   100,000 
    Accounts receivable, net 4,380,518   5,321,037 
    Other receivables 1,855,000   1,999,637 
    Loan receivable (related party) 4,375,892   4,375,059 
    Prepaid expenses (including related party amount of $508,879 and $312,966, respectively) 2,170,263   1,859,563 
    Inventory, net 2,346,487   1,716,552 
    Total Current Assets 15,406,042   16,059,768 
            
    Intangible assets, net 250,000   283,333 
            
    Total Assets$15,656,042  $16,343,101 
            
    Liabilities and Stockholders' Deficit       
    Current Liabilities:       
    Accounts payable and accrued liabilities (including related party payable of $217,956 and $88,644, respectively)$3,098,590  $5,191,868 
    Income taxes payable 77,564   242,977 
    Contract liabilities 36   24,252 
    Short term loans payable, net of debt discount 4,754,555   7,725,272 
    Current portion of long-term notes payable, net of debt discount and debt issuance cost, related party 135,000   4,000,000 
    Total Current Liabilities 8,065,745   17,184,369 
            
    Long-term Liabilities:       
    Notes payable, net of debt discount, related parties 12,333,053   8,333,053 
    Notes payable 10,896,610   7,457,022 
    Total long-term liabilities 23,229,663   15,790,075 
    Total Liabilities 31,295,408   32,974,444 
            
    Commitments and contingencies       
            
    Stockholders' Deficit:       
    Common stock, $0.00001 par value; 300,000,000 shares authorized; 8,752,178 and 8,721,818, shares issued, respectively; 8,572,105 and 8,541,745 outstanding, respectively 88   87 
    Additional paid in capital 27,761,307   27,643,660 
    Accumulated other comprehensive loss (49,712)  (47,777)
    Accumulated deficit (43,223,549)  (44,099,813)
    Less: Treasury stock (180,073 shares) at cost (127,500)  (127,500)
    Total stockholders' deficit (15,639,366)  (16,631,343)
    Total Liabilities and Stockholders' Deficit$15,656,042  $16,343,101 
            



    Synergy CHC Corp.

    Unaudited Condensed Consolidated Statements of Income and Comprehensive Income

          
     For the three months ended  For the three

    months ended
     
     March 31,

    2025
      March 31,

    2024
     
    Revenue       
    Product Sales 6,670,534  $9,411,863 
    License Revenue 1,500,000   - 
    Total Revenue 8,170,534   9,411,863 
            
    Cost of Sales 2,006,513   2,637,139 
            
    Gross Profit 6,164,021   6,774,724 
            
    Operating expenses       
    Selling and marketing 2,876,271   3,584,677 
    General and administrative 1,306,714   1,348,385 
    Depreciation and amortization 33,333   33,333 
    Total operating expenses 4,216,318   4,966,395 
            
    Income from operations 1,947,703   1,808,329 
            
    Other (income) expenses       
    Interest income (13,882)  (387)
    Interest expense 1,095,369   1,109,980 
    Remeasurement loss (gain) on translation of foreign subsidiary 1,412   (8,983)
            
    Total other expenses 1,082,899   1,100,610 
            
    Net income before income taxes 864,804   707,719 
    Income tax benefit (expense) 11,460   (127,189)
            
    Net income after tax$876,264  $580,530 
            
    Net income per share – basic$0.10  $0.08 
    Net income per share – diluted$0.10  $0.08 
            
    Weighted average common shares outstanding       
    Basic 8,560,636   7,373,745 
    Diluted 8,577,620   7,373,745 
    Comprehensive income:       
    Net income$876,264  $580,530 
    Foreign currency translation adjustment (1,935)  131,637 
    Comprehensive income$874,329  $712,167 
            



    Synergy CHC Corp.

    Unaudited Condensed Consolidated Statements of Cash Flows

          
     For the three

    months ended
      For the three months ended 
     March 31,

    2025
      March 31,

    2024
     
    Cash Flows from Operating Activities     
    Net income$876,264  $580,530 
    Adjustments to reconcile net income to net cash used in operating activities:       
    Amortization of debt discount and debt issuance cost 406,841   - 
    Depreciation and amortization 33,333   33,334 
    Foreign currency transaction loss (gain) (3,137)  11,178 
    Remeasurement gain on translation of foreign subsidiary (1,412)  (8,983)
    Non cash implied interest -   7,199 
    Changes in operating assets and liabilities:       
    Accounts receivable 940,519   (318,330)
    Other receivables 144,637   - 
    Loan receivable, related party (833)  25,162 
    Inventory (629,935)  1,016,455 
    Prepaid expenses (114,787)  (202,888)
    Prepaid expense, related party (195,913)  (165,687)
    Income taxes payable (165,413)  (20,315)
    Contract liabilities (24,216)  12,932 
    Accounts payable and accrued liabilities (2,218,041)  (1,808,989)
    Accounts payable, related party 129,312   (19,640)
    Net cash used in operating activities (822,781)  (858,042)
            
    Cash Flows from Investing Activities -   - 
            
    Cash Flows from Financing Activities       
    Advances from related party 135,000   1,400,000 
    Repayment of notes payable, related party -   (84,500)
    Proceeds from notes payable 1,496,250   125,000 
    Repayment of notes payable (1,316,572)  (435,880)
    Net cash provided by financing activities 314,678   1,004,620 
            
    Effect of exchange rate on cash, cash equivalents and restricted cash (1,935)  131,637 
    Net decrease in cash, cash equivalents and restricted cash (510,038)  278,215 
            
    Cash and restricted cash, beginning of year 787,920   732,534 
    Cash and restricted cash, end of period$277,882  $1,010,749 
            
    Supplemental Disclosure of Cash Flow Information:       
    Cash paid during the period for:       
    Interest$573,529  $1,102,781 
    Income taxes$-  $147,728 
            
    Supplemental Disclosure of Noncash Investing and Financing Activities:       
    Accounts payable converted to loan payable upon settlement$-  $3,770,824 
    Issuance of common stock for loan financing$117,648  $- 


    Primary Logo

    Get the next $SNYR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Leadership Updates

    Live Leadership Updates

    See more
    • Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

      WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

      5/29/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

      ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

      1/21/25 9:10:17 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Financials

    Live finance-specific insights

    See more
    • Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

      WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

      5/15/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information

      WESTBROOK, Maine, May 01, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the first quarter ended March 31, 2025, on Thursday, May 15, 2025, before the open of market trading. In conjunction with reporting first quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

      5/1/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces Fourth Quarter and Full Year 2024 Earnings and Conference Call Information

      WESTBROOK, Maine, March 20, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the fourth quarter and full year ended December 31, 2024, on Monday, March 31, 2025, before the open of market trading. In conjunction with reporting fourth quarter and full year 2024 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Syner

      3/20/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 5:05:31 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $39,350 worth of shares (14,340 units at $2.74), increasing direct ownership by 4% to 361,207 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 4:46:18 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $59,521 worth of shares (15,200 units at $3.92), increasing direct ownership by 5% to 346,877 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      3/3/25 9:25:39 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Synergy CHC Corp.

      10-Q - Synergy CHC Corp. (0001562733) (Filer)

      5/15/25 8:05:55 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Synergy CHC Corp. (0001562733) (Filer)

      5/15/25 8:00:17 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by Synergy CHC Corp.

      DEFA14A - Synergy CHC Corp. (0001562733) (Filer)

      4/28/25 4:20:08 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Synergy CHC Announces Appointment of Erik Shields as Vice President of Beverage

      WESTBROOK, Maine, May 29, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that Erik Shields has been named Vice President of Beverage of Synergy, effective May 26, 2025. "We're excited to welcome Erik to the team and look forward to his contributions," said Jack Ross, CEO of Synergy. "With nearly two decades of experience leading national strategies, managing key accounts, and building high-performance teams, Erik brings the leadership and executional expertise needed to help scale our beverage business. As we focus on accelerating growth in this category, we're confident he w

      5/29/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp Reports Growth in Earnings Per Share for its First Quarter 2025 Financial Results and its Ninth Consecutive Quarter of Profitability

      WESTBROOK, Maine, May 15, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, is announcing its financial results for the three months ended March 31, 2025. "We are very pleased to report 30% growth in earnings per share year-over-year, marking our ninth consecutive quarter of profitability," said Jack Ross, CEO of Synergy. "Additionally, we expanded our EBITDA margins significantly to 24.1% compared to 19.7% in the prior year period. This performance highlights the strength of our operating model and our ongoing discipline around cost management." "We continue to make meaningful progress toward

      5/15/25 8:00:00 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • Synergy CHC Corp. Announces First Quarter 2025 Earnings and Conference Call Information

      WESTBROOK, Maine, May 01, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a provider of consumer health care and lifestyle products, announced today that it plans to release financial results for the first quarter ended March 31, 2025, on Thursday, May 15, 2025, before the open of market trading. In conjunction with reporting first quarter 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's website. To access the call by

      5/1/25 4:05:00 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D filed by Synergy CHC Corp.

      SC 13D - Synergy CHC Corp. (0001562733) (Subject)

      10/31/24 9:55:58 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Synergy CHC Corp.

      SC 13G - Synergy CHC Corp. (0001562733) (Subject)

      10/25/24 7:46:44 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 5:05:31 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $39,350 worth of shares (14,340 units at $2.74), increasing direct ownership by 4% to 361,207 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      5/21/25 4:46:18 PM ET
      $SNYR
      Other Pharmaceuticals
      Health Care
    • CEO and Chairman Ross Jack bought $59,521 worth of shares (15,200 units at $3.92), increasing direct ownership by 5% to 346,877 units (SEC Form 4)

      4 - Synergy CHC Corp. (0001562733) (Issuer)

      3/3/25 9:25:39 AM ET
      $SNYR
      Other Pharmaceuticals
      Health Care